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HOW ARE DRUG THERAPEUTIC LEVELS MAINTAINED WHILE 
AVOIDING DANGEROUS SIDE EFFECTS ASSOCIATED WITH 
CONVENTIONAL IMMEDIATE-RELEASE DOSAGES? 
Chedva Farkas 
INTRODUCTION 
Ever since the discovery of bacteria and their role in the disease process in the 
mid-1800s, scientists have been heavily involved in the discovery and development of 
drug therapies and their mechanism of action in the human body.  Shortly after the 
initial discovery came the era of drug discovery of the late 1800s-early 1900s, also 
known as the “drug revolution” (Dash and Cudworth 1998).  Although the drug 
revolution led to the rapid discovery of many new drugs, pharmacological factors such 
as dosage forms, drug delivery systems, plasma drug levels, and how all these factors 
contribute to the efficacy of a drug were poorly understood.  It wasn’t until the mid- 
1900s that these factors were identified (Dash and Cudworth 1998).  One particular 
factor which, once discovered, turned into a main focus in pharmacological research 
and lead to improvements in drug efficacy is centered on the importance of 
maintaining a steady therapeutic drug concentration level in the plasma.   
The most conventional method for drug administration has always been 
through the use of oral products, such as tablets and capsules.  These conventional oral 
drug products are formulated to release the active drug immediately after oral 
administration to obtain complete and rapid drug absorption in the body and 
immediate therapeutic effects (Shargel et al. 2004).  However, once the body fully 
absorbs the drug, plasma drug concentration levels decline precipitously, possibly 
falling below the minimum effective plasma concentration (MEC), resulting in a loss of 
therapeutic activity.  Before falling below MEC, the patient must be administered 
another dosage to maintain therapeutic effects (Shargel et al. 2004).  Clearly, the 
conventional dosage form leads to a peak-and-valley curve of drug plasma levels 
versus time.  This peak-and-valley pattern can have adverse effects since peaks, high 
plasma concentration of drugs (a result of frequent dosing), can cause toxicity, and 
valleys, low drug concentration in the plasma, may lead to sub-therapeutic levels and a 
possible buildup of drug resistance by the body’s immune system (Dash and Cudworth 
1998).  How are drug therapeutic levels maintained while avoiding dangerous peak-
and-valley side effects that often occur after the administration of conventional 
immediate-release dosage forms? 
In order to maximize the therapeutic effectiveness of a drug while avoiding 
potential side effects that result from large fluctuations in drug blood levels, optimal 
concentration of drug in blood plasma must be sustained continuously (Breimer et al. 
1984).  In the past, the only known way to maintain a steady concentration of a drug’s 
level in the plasma was through intravenous (IV) administration of the drug at a 
constant rate.  Although steady IV administration is effective, it generally requires a 
health care professional to monitor the plasma drug concentration and cannot be 
performed at home (Dash and Cudworth 1998).  In recent years, continued advances 
in pharmaceutical sciences have given rise to modern technological processes which 
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provide alternate drug delivery systems that can maintain a steady therapeutic drug-
plasma level while avoiding the inconveniences of IV administration and the possible 
dangers of frequent oral dosing (Chen et al. 2010).  “Modified-release drug products” 
is the general term used by the US Pharmacopeia (USP) to describe products that 
“alter the timing and/or rate of release of the drug product to accomplish constant 
therapeutic levels not offered by conventional immediate release products” (Chen et al. 
2010).   
A major subdivision of modified-release products includes drug products with 
extended-release (also referred to as controlled-release) characteristics.  Examples of 
extended-release drug products primarily include prolonged-action drug products and 
sustained-release drug products.  Prolonged-action drug products are designed to 
slowly release the active drug substance in a way that provides a continuous supply 
over a period of time, 
thereby avoiding rapid 
and peak drug 
absorption in the 
plasma.  Sustained-
release drug products 
are designed to deliver 
an initial therapeutic 
dose followed by a 
slower steady release 
of drug that equals the 
rate of drug elimination 
from the body, 
resulting in minimal 
plasma drug 
concentration 
fluctuations (Shargel et 
al. 2004).  Figure 1 
portrays a plasma drug 
concentration versus 
time profile for both oral and sustained release delivery systems.  This graph proves 
the value of an extended-release drug delivery system over the conventional frequent 
oral dosage since the sustained-release delivery system clearly stays in the desirable 
therapeutic and relatively homeostatic level while the oral immediate-release pill 
fluctuates between toxic and ineffective levels (Dash and Cudworth 1998).  Currently, 
extended-release drug products encompass a wide range of products ranging from 
extended-release oral products, transdermal patches, and even implantable drug 
systems.   
Before investigating the actual pharmaceutical applications used to create 
extended-release drug products, it is important to understand the possible 
biopharmaceutical factors that determine how a drug works in the gastrointestinal 
tract and the various pharmacokinetic properties that determine a drug’s rate of 
absorption and release in the human body.      
Figure 1: plasma drug concentration versus time profile for both oral and 
sustained release delivery systems. Source: Dash and Cudworth 1998 
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DRUG- ABSORPTION 
As mentioned above, modified-release pharmaceutical preparations are 
generally designed to produce drugs with slow and uniform in-vivo absorption.  In 
view of the fact that many of these oral modified release drugs are designed to remain 
intact in the gastrointestinal (GI) tract longer than the original immediate-release 
drugs, the anatomy and physiology of the GI tract plays a key role in the dosage and 
absorption of these drug products (Shargel et al. 2004).  There are a number of 
physiological factors along the GI tract that affect drug release rate and uptake from 
the modified-release product. They include variations in pH, GI motility phases, 
presence of food, gastric emptying, presence of bacteria, enzymatic activities, varying 
permeability along the GI tract, volume of intestinal juice, and other factors as well 
(Lobenberg et al. 2000).  Clearly, in-vivo behavior of modified-release oral drugs can 
be extremely complex considering all of the interacting mechanisms and changes 
occurring at every second in the gut (Varum et al. 2010).  Researchers have, therefore, 
studied gut physiology and the mechanisms of digestion extensively with the hope that 
they can get a grasp on the in-vivo mechanisms and thereby produce maximally 
effective modified-release drugs.   
The stomach is the first organ along the gastrointestinal track that a drug 
reaches.  The general role of the stomach in the digestive system is to mix entering 
foodstuffs with digestive juices and then empty this mixture periodically into the small 
intestine (Shargel et al. 2004).     Although this may seem to be a simple and 
predictable cycle, the movement of food and drugs through the stomach is greatly 
affected by the physiological state of the stomach, thereby affecting the time and 
location of the release of a drug from its dosage form (Shargel et al. 2004 and Varum et 
al. 2010).  One particularly significant physiological factor which affects the ultimate 
time a drug is released from its dosage form depends upon the presence or absence of 
food in the stomach at the time of drug intake.   
FACTORS THAT INFLUENCE ABSORPTION 
The presence or absence of food has a major role in gastric emptying and 
gastric retention (Varum et al. 2010).  In the presence of food, the stomach is 
considered to be in a digestive phase, whereas when lacking food, the stomach is 
considered to be in an interdigestive phase (Shargel et al. 2004).  In the interdigestive 
phase, also known as the fasted state, gastric motility is under the control of a series of 
cyclical fluctuations in contractile activity commonly referred to as the migrating 
motility complex (MMC) (Higaki et al. 2008).  The MMC is composed of four phases 
and can take up to about 30-40 minutes to be completed.  Phase I is characterized by a 
total lack of activity.  Phase II follows with an increase in the number and intensity of 
contractions.  Phase III is characterized by large-amplitude peristaltic contractions 
that end with a strong “housekeeper contraction” which causes a massive gastric 
emptying of everything left in the stomach.  Phase IV is an intermediate phase and acts 
as a transition period between the strong contractions of Phase III and Phase I of the 
next MMC cycle (Higaki et al. 2008 and Shargel et al. 2004).  In the presence of food, 
on the other hand, MMC is basically abolished and low-amplitude peristaltic 
contractions take over, enabling gastric emptying of only small molecules into the 
duodenum (Higaki et al. 2008).  Food particles larger than 2mm are retained in the 
stomach during the digestive phase (Shargel et al. 2004).  Clearly, gastric emptying of 
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drugs (particularly tablets larger than 2mm) occurs mainly during Phases II and III of 
MMC in the fasted state (Higaki et al. 2008).  Therefore, drugs larger than 2mm that 
are administered during a fasted state will be emptied out of the stomach fairly quickly, 
leading to a faster release of the drug into the patient’s plasma.  However, if the same 
large drug is administered in the digestive stage, it may remain in the stomach for a few 
hours until Phase II/III of the next MMC occurs.   
Another factor that is known to have an important effect on gastric emptying 
and gastric retention is the caloric content of meals eaten around the time of drug 
administration.  High caloric content meals generally show a delay in gastric emptying 
of both food and drug.  In one particular study, a multiple-unit dose failed to empty for 
up to ten hours post-dosing in volunteers who consumed a high caloric meal (Varum et 
al. 2010).  If, for example, a certain drug is modified to be released a few hours after 
administration with the intent that, at that time, the drug will be in the small intestine, 
a highly caloric meal might retain the drug in the stomach for too long and lead to a 
release of the drug in the stomach instead of the small intestine.  Clearly, researchers 
can greatly benefit from knowledge of factors affecting gastric retention and emptying 
when formulating modified-release dosages. 
Many studies were done to determine the effects of the fed/fasted state along 
with the caloric content of a meal on gastric emptying of a modified- release drug.  One 
experiment in particular hypothesized that gastric emptying of different-sized enteric-
coated pellets (enteric coating of pellets is a modified-release formulation characteristic 
that prevents dissolution in the stomach but allows rapid dissolution in the small 
intestine) would occur at different rates with the smaller pellets emptying in the fed 
state and the larger pellets emptying in the fasted state (Rhie et al. 1998).  In this 
experiment, 12 healthy individuals were each given 0.7mm caffeine (CAFF) and 
3.6mm acetaminophen (APAP) along with a viscous caloric meal at levels of 4000, 
6000, and 8000 cP.  The CAFF and APAP pellets were both enteric-coated spherical 
pellets formulated with sucrose nonpareils as the core which was coated with several 
suspension layers of the active ingredient, thereby achieving a target diameter, drug 
potency, and enteric coat level to aid in the release of the drug at a specific location.  
Gastric motility patterns were recorded using the monometric catheter, a technological 
device where the peaks on the machine represent the start and end of the different 
stages, such as Phases II and III of the MMC cycle.  Blood samples were also obtained 
throughout the experiment in order to assess the plasma profiles of the drug, focusing 
specifically on the time when the drug was first detected in the plasma.  Plasma results 
demonstrated that CAFF from the 0.7mm enteric-coated pellets were consistently 
(with all the different caloric level meals) measured in the plasma before the APAP 
from the 3.6mm enteric-coated pellets.  Additionally, upon observing the timing of the 
release of the pellet dose, the results indicated that plasma profiles were strikingly 
superimposable upon the gastric motility patterns noted by the monometric catheter 
(especially with the 4000 cP meal); the time that CAFF from the smaller pellet was 
detected in the plasma correlated with the spikes on the monometric catheter which 
represented a fed state phase, backing up the assumption that small pellets are released 
from the stomach during the digestive phase.  In contrast, APAP pellets were first 
observed in the plasma at the same time as the onset of the fasted contractile activity 
(Phases II and III).  Overall, the meal viscosity levels in this experiment did not 
significantly affect the rate of drug absorption (Rhie et al. 1998).  Knowledge of how 
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factors of gastric emptying affect the release of a drug assists in the development of 
modified release drugs that can take advantage of these factors.  
It is important to note that, although most studies prove that a larger dosage 
form results in longer gastric retention, there have been studies that proved that 
different size dosages had no effect on the timing of gastric emptying.  Clearly, more 
research should be done on this complex issue.  Perhaps one of the many other 
physiological factors in the stomach, such as a pH level of 1-2 in the presence of food 
and 3-5 in the absence of food, can alter gastric emptying times if the experiment is not 
properly controlled.  
The stomach empties its contents into the small intestine which provides a large 
surface area for drug absorption and where transit time of solids takes approximately 
3-5 hours (Varum et al. 2010).  Data obtained from various research projects is too 
varying to make conclusions on the effects fed and fasted states have on the transition 
of dosage forms along the small intestine.  However, it was observed in numerous 
studies that the administration of modified-release multiple-unit enteric-coated dosage 
forms before eating resulted in a faster small intestinal transit time compared with the 
transit time of the drug in a fasted state (Varum et al. 2010).  This information is 
extremely valuable.  For example, if a drug is meant to be absorbed in the proximal 
small intestine, such a drug should be administered in pre-fed patients, resulting in 
modified-release of the drug in the upper GI tract.  Administration of the drug in a 
fasted state might give the drug enough time to travel as far as to the colon where 
colonic conditions may make it impossible to be absorbed.  Additionally, the presence 
of bacteria in the terminal part of the small intestine and its pH level of about 6 may 
also affect drug release in the small intestine.   
The large intestine is the next and last step for a drug to be absorbed in the GI 
tract.  A lack of fluids in the colon, besides for in the rectum, makes it difficult to 
absorb drugs passing through.  The presence of bacteria in the colon can perhaps 
affect the absorption of modified-release drugs in the colon as well (Shargel et al. 
2004).   
The high variability in GI transit presents significant implications for the in-
vivo performance of drugs in modified-release systems that are intended to delay or 
sustain release of drugs (Varum et al. 2010).  The following studies represent how 
modified-release drug products can take advantage of the physiological conditions of 
the GI tract.  Scientists do numerous studies on the gastrointestinal effects on a drug 
before creating a modified-release version of the drug.  The majority of these 
experiments use the novel technique of pharmaco-scintography to assess regional drug 
absorption in humans.  This technique works by co-administering a radiolabeled 
placebo pellet along with the coated modified-release drug of choice.  The radiolabeled 
pellet’s gastrointestinal transit is then monitored through a gamma camera.  Blood 
samples are also generally collected periodically to assess plasma concentration of the 
drug in question and then compared to the scintigraphic results to help determine the 
exact time and gastrointestinal location of drug release (Basit et al. 2004).   
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One specific study was performed to evaluate the GI transit, release, and 
absorption of budesonide, a drug used for the treatment of inflammatory bowel disease 
(IBD), from its mutimatrix MMX® formulation. Budesonide’s MMX formulation is 
designed to release the drug throughout the entire colon at a controlled rate (Brunner 
et al. 2006).  Previously, budesonide had only been formulated to treat IBD in the 
right-sided colonic region in Chron’s disease, and in left-sided ulcerative colitis.  
Therefore, in order to orally treat distally located IBD, gastric- resistant, extended-
release budesonide tablets characterized by a multimatrix structure have been 
developed to allow a prolonged and steady release of budesonide along the entire colon 
at a controlled rate.  This experiment 
tested the efficacy of the drug’s 
prolonged-release characteristics on 
twelve healthy males.  The volunteers 
were administered the budenoside 
multimatrix tablets, along with a 152Sm-
oxide tablet that was transformed into a "-
ray-emitting compound to be used for 
scintigraphy.  Scintigraphic scans and 
blood samples were taken and compared 
periodically.  MMX®-budesonide tablets 
were detected by scintigraphic imaging in 
the ascending colon between 4 and more 
than 24 hours after dosing, as is depicted 
in 2, and the drug left the descending 
colon at 12 to more than 24 hours post-
dosing. 
An estimated 96% of the 
budesonide was absorbed in the target region (between the ascending and descending 
colon) as was calculated by the area under the curve (AUC), represented by the 
AUCtarget/AUC24 ratio where the AUCtarget represented the plasma AUC where 
radioactivity was detectible in the target region, and the AUC24 was attained from the 
plasma AUC values of budesonide observed over the entire 24-hour period (Brunner 
et al. 2006). Clearly, this modified budenoside formulation was successful in delivering 
its active drug throughout the entire colon.  Additionally, although budesonide plasma 
concentrations were first observed after 6.8 ± 3.2 h, maximum plasma concentrations 
were reached about seven hours later.  The time difference between the initial 
detection of budesonide in the plasma and budesonide’s time of max concentration 
(tmax) verifies the sustained-drug release characteristics of the budesonide MMX® 
tablets.   
Phase two of this experiment tested the effect of food on budesonide 
pharmacokinetics.  Plasma samples taken after the administration of a highly caloric 
and fatty meal reflected the fact that budesonide absorption decreased by 30% in 
relation to those who took the pill under fasted conditions (Brunner et al. 2006).  This 
decrease of drug absorption may justify the administration of this drug with a meal to 
limit its potency and thereby improve the safety profile as a drug.  Conclusively, the 
formulation of  MMX®-budesonide tablets have clearly utilized knowledge of 
gastrointestinal transit as an aid in producing a sustained-release drug suitable for 
Figure 2: Scintigraphic imaging of the colon. 
Source: Brunner et al. 2006   
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targeted drug-delivery to the colon.  However, further research should be done on this 
subject, since colonic infected individuals, for whom this drug is meant, may react 
differently to the drug than healthy individuals on whom the experiment was done.   
Another study evaluated the absorption of the drug Ipsapirone along the 
human GI tract.  In man, Ipsiparone, an anti-depressant, has an absorption half-life of 
less than 0.25 hours and an elimination half-life of about 1-3 h.  This noticeably rapid 
absorption leads to a rapid peak in plasma concentration of the drug which often 
causes vertigo, dizziness, and dysphoria (Fuhr et al. 1994).  Researchers have, 
therefore, studied the bioavailability (a term used to describe the fraction of an 
administered dose of unchanged drug that reaches the systemic circulation) of 
Ipsapirone after its administration at different regions of the GI tract to help develop 
an effective and safe modified-release drug.  Researchers hoped that a modified-release 
version of Ipsapirone would reduce unwanted side effects since the modified-release 
dosage form does not release its entire dose in one region, thereby avoiding a rapid 
plasma peak of the drug.  Ipsapirone-HCl was administered to four healthy males 
orally, rectally, and locally in different locations along the GI tract by a remote control 
drug delivery device.  Plasma results indicated that there was a 2-3-fold increase in the 
bioavailability of the drug administered directly into the colon than when the drug was 
administered into the upper GI tract.  This 2-3-fold increase indicates an equivalence 
of a 5 mg dose of ipsapirone-HCl released in the colon with a 10-15 mg dose given 
orally.  Oral doses of this size (10-15 mg) were tolerated, and administration of 5 mg 
ipsapirone into the colon was deemed safe.  These results fulfill the criteria for the 
development of a prolonged-release preparation with 5 mg ipsapirone-HCl.  Through 
modifications of the drug’s coating, the drug could be modified to be released only in 
the colon; such a modification makes it unnecessary to administer a full 10-15 mg 
immediate-release dose which loses most of the drug by the time it reaches the colon.  
Considering the fact that this was a small sample of only four males, further research 
should be done to test if rectal administration of this drug to the colon really equals 
oral prolonged-release administration (Fuhr et al. 1994). 
An example of a new oral modified-release drug that was formulated based on 
knowledge and applications of the varying characteristics of the GI tract is Rifamycin 
SV MMX (Di Stefano et al. 2011).  Rifamycin SV is an oral, non-absorbable antibiotic 
which can be used in the treatment of colonic bacterial infections.  These tablets are 
formulated using a multimatrix structure which, like budesonide, delivers the active 
drug ingredient (200mg of sodium rifamicyn SV) directly to the colon.  In immediate-
release drugs, the active ingredient would be released immediately upon 
administration, and maximum bioavailability in the colon would not be achieved (Di 
Stefano et al. 2011). With the modified-release tablets, however, the maximum 
bioavailability of the active ingredient is achieved, and the biological effect is optimized 
at the target region, the colon.   
The Rifamicyn SV MMX tablet contains a double-matrix system.  
Microparticles of the active ingredient are dispersed in a lipophilic matrix which is in 
turn dispersed in a hydrophilic matrix.  The hydrophilic coating inhibits the 
penetrations of fluids into the tablet, thereby lowering the rate of drug dissolution in 
the upper GI tract.  The tablet is coated with a pH dependent, gastro-resistant polymer 
film which also inhibits dissolution of the tablet in the upper GI tract.  This MMX 
tablet begins to disintegrate when the pH is %7.  With the pH-sensitive and hydrophilic 
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coating, the tablet reaches the cecum intact and it is there that the release of the drug 
begins.  The pH-sensitive coating disintegrates, and the intestinal fluids interact with 
the hydrophilic coating which forms an outer gel mass that slows diffusion of the 
antibiotic into the colonic lumen (Di Stefano et al. 2011).  As the tablet progresses 
towards the rectum, debris of the gel mass disaggregates and releases the antibiotic 
directly near the mucosa of the rectum.  Studies done through pharmaco-scintigraphic 
investigations clearly demonstrate an effective colonic delivery of this drug, supporting 
the production of rifamycin in a modified-release formulation.  
These studies all give us valuable insight into the natural absorption of different 
drugs. Using this knowledge allows for the creation of drugs specially suited for 
different releases.  
PHARMACOKINETICS  
Pharmacokinetics is the study of the time-course of drug concentrations in the 
body, based on various characteristics of drug absorption, distribution, metabolism, 
and excretion (Mager 2006). As stated above, conventional drug delivery systems very 
often rely on frequent dosing in order to attain a therapeutic level, which leads to large 
fluctuations in drug blood levels.  The frequency at which a conventional dosage must 
be given is dependent on two pharmacokinetic properties: elimination half-life (t1/2) 
and therapeutic index (TI) (Sood and Panchagnula 2003).  Half-life is the time 
interval in which half of the active drug in a system is lost, and therapeutic index is the 
concentration range in which a drug works (Sahin and Benet 2008).  Knowing the 
half-life of a drug assists pharmaceutical companies in setting dosage frequency 
intervals so that the right amount of active drug will be in circulation at all times, since 
the dosing interval directly influences the ratio of maximum (Cmax) to minimum (Cmin) 
blood drug concentrations.  Although this seems quite simple, it should be noted that 
there are many other factors involved in half-life and other pharmacokinetic properties 
and equations which are beyond the scope of this paper.  Obviously, drugs with 
shorter half-lives require a more frequent administration in order to keep blood-drug 
concentration levels within the therapeutic index.  The goal of controlled-release drugs 
is to release the active drug ingredient at a sufficient rate, frequency, and dose so that 
the ratio Cmax/Cmin is maintained at an effective steady state throughout the therapy 
without having to be so dependent on half-life and therapeutic indexes which often 
leads to the necessity of frequent dosing (Sood and Panchagnula 2003).  Drugs with 
zero-order kinetics are generally the easiest to deal with when producing controlled-
release dosage forms because they are predictable.  They release the active ingredient 
at a constant rate that is independent of the concentration of the reactants; it is much 
easier to create a modified-release formulation when the drug’s exact rate of release is 
already known.     
RELEASE CONTROL MECHANISM  
The knowledge of the gastrointestinal and pharmacokinetic implications on a 
drug’s efficacy aided researchers in manufacturing extended-release drugs which can 
help in lowering the fluctuations in blood-drug levels.  Most extended-release drugs 
are manufactured through the use of a matrix structure.  The drug is suspended or 
dissolved within the matrix and/or within a rate-controlling membrane through which 
the drug diffuses (Shargel et al. 2004).  In this context, the matrix refers to an inert 
solid in which the drug is suspended throughout and diffuses out of quite slowly.  
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There are basically three different types of modified release matrix mechanisms.  In the 
first type, the drug is dissolved in a matrix material that is coated with a soluble 
coating. In such a case, the rate of drug release depends entirely on the matrix 
material; a porous matrix will lead to a fast absorption of water, resulting in rapid drug 
release from the matrix material, whereas a less porous matrix will not absorb much 
water right away and will, therefore, cause a slower and lengthier drug release.  The 
second system is that of a matrix with an insoluble membrane.  When a drug is 
prepared in such a manner, its release is not only dependent on the permeability of the 
matrix; it is dependent on the membrane’s permeability as well.  The third system is a 
matrix tablet with a combined membrane where the membrane becomes porous after 
dissolving the soluble part of the membrane in water.  Aside from matrix and 
membrane factors in creating extended-release products, most extended-release drugs 
release their drug product as a result of a combination of processes including 
dissolution, permeation, and diffusion.  Water permeation is probably the most 
important factor that drug manufacturers consider since, as the influx of water into the 
product is controlled, the rate at which the drug dissolves is essentially controlled.  
Once the drug dissolves, drug diffusion out of the tablet/capsule is further controlled 
by the permeability of the membrane (Shargel et al. 2004). All of these factors are 
considered and used to aid in the development of modified-release drugs.   
ORAL EXTENDED-RELEASE 
Of all the different kinds of extended-release products, oral extended-release 
products prove to be the simplest and easiest to manufacture, lowest cost, high level of 
reproducibility, and stability (Siddique et al. 2010).  The following examples touch the 
surface of the numerous kinds of applications that can modify the release of oral drugs 
to maintain homeostatic conditions in the human body.   
GUM-TYPE MATRIX TABLETS 
Gum-type matrix tablets are manufactured with a matrix that swells in the 
presence of water to form a gel-like consistency.  This gel is generally very thick and, 
therefore, provides a barrier for drug diffusion out of the tablet.  Such a matrix is 
commonly formed with excipients (carrier of active drugs) such as methylcellulose, 
gum tragacanth, Veegum, and alginic acid.  The thickness of the gel caused by these 
excipients provides controlled-release results in that they prevent drug dissolution 
until the gel-like matrix breaks up and the drug completely dissolves and gradually 
diffuses into the intestinal fluid (Shargel et al. 2004).   
Diazepam, a benzodiazepine drug used for acute management of severe 
seizures, is an example of a drug that has been manufactured in a gum-type matrix 
tablet, thereby providing sustained-release of this drug for hours (Shargel et al. 2004).  
A study was done on Diazepam which investigated the feasibility of incorporating 
Diazepam, a poorly water-soluble drug, into solid-lipid nanoparticles (such as a gum-
type matrix) that can offer rapid onset (for early termination of seizures) and 
prolonged-release of the drug for long-acting protection against further seizures.  The 
particular characteristics of the solid-lipid nanoparticles (SLNs) used (such as the 
SLN’s biocompatible lipid core but ampiphillic outer shell in this case) allowed for 
immediate and prolonged release which, in essence, is the main characteristic of a 
sustained release drug system.  Different SLN formulations were then tested to see 
which combination of lipid matrices and surfactant would result in the best prolonged-
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release results.  (SLN formulations composed of Tween 80 as a surfactant and lipid 
matrix of 5% Compritol ATO 888 and 5% Imwitor 900k provided the best in vitro 
prolonged-release effects for diazepam (Abdelbary and Fahmy 2009).)   
Clearly, a gum-type/lipid matrix is one effective manner of prolonging the 
release of a drug, thereby preventing the need of frequent dosing and dangerous 
fluctuations of blood drug levels.  However, it should be noted that since this 
experiment tested results in vitro, more research should be done to obtain in vivo 
results which would be more beneficial in determining the actual effects of such drugs 
in the human body.                   
POLYMERIC MATRIX TABLETS 
Of recent, drug manufacturers have been very interested in using polymeric 
material in the matrix to prolong the rate of drug release.  The significance of 
polymeric matrix tablets over other kind of matrix tablets is that polymeric matrix 
tablets can prolong the release of a drug to last for days or even weeks (Shargel et al. 
2004).  The polymers that are available for drug formulation include hydrophilic 
polymers, such as polylactic acid and polyglycolic acid, and hydrophobic polymers, 
such as ethylene-vinyl acetate copolymer (EVA).  The hydrophilic polymers release 
the drug gradually while the hydrophobic polymers release the drug over a much 
longer period of time because of its hydrophobic characteristic which blocks water 
from entering and causing drug dissolution.  Additionally, the rate of drug release can 
be further controlled by combining different polymers, such as adding a hydrophobic 
polymer to a hydrophilic one to decrease the rate of the drug’s release.  Light, heat, 
and other factors may also be administered to change the properties of the polymers 
being used (Shargel et al. 2004). 
One particular study investigated the influence of polymer level and type of 
some hydrophobic polymers including hydrogenated castor oil; Eudragit RS100; 
Eudragit L100; and some fillers, mainly mannitol; dibasic calcium phosphate 
dihydrate; and anhydrous dibasic calcium phosphate on the release rate and 
mechanism of the drug baclofen.  Results showed that a high polymeric content (40%) 
in the matrix lowered the release rate of baclofen, whereas a low polymeric content 
(20%) elevated the rate of drug release from the matrix.  Additionally, hydrogenated 
castor oil was proven to be the polymer that caused the strongest retardation of drug 
release (Abdelkader et al. 2008).  Thus, in addition to knowing the kinetics and half-
life of a particular drug, the correct combination of polymers can be formulated to 
bring about the perfect amount and rate of drug release.   
MULTIPLE UNIT PELLETS 
Modified-release dosage forms which have been proven to control the release of 
the active drug, thereby reducing the side effects associated with peak and trough drug 
plasma levels, have been improved upon in the development of modified-release 
multiple unit pellets.  Whereas single-unit formulations contain the active ingredient 
within one single tablet or capsule, multiple-unit dosages are manufactured so that a 
number of discrete particles are combined into one dosage form.  These particles could 
come in the form of pellets, granules, sugar seed (non-pareils), mini-tablets, or 
powders which contain within them the active ingredient.  One advantage of multiple 
unit pellets over single unit pellets is that when taken orally, multiple unit pellets 
spread over a large surface in the GI tract, and the particles behave like liquids that 
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can leave the stomach shortly after entering 
without waiting for the series of waves to 
push them along the GI tract (Abdul et al. 
2010).  In addition, the fact that the pellets 
disperse throughout the GI tract improves 
the drug’s bioavailability and can reduce 
drug concentration in a specific location 
which might otherwise have lead to toxicity.  
Additionally, sometimes if a drug is released 
too early along the GI tract, it can irritate the 
gastric mucosa.  Multiple unit pellets 
definitely reduce the risks associated with 
premature drug release because of the rapid 
transition of smaller enteric-coated pellets 
along the GI tract.  Failure of some of these 
units from reaching their target will also not 
be as consequential as the failure of a single-
unit dose.  Theophylline (Gyrocap) is an 
early example of a beaded form extended-
release pellet (Shargel et al. 2004).  The frequency of adverse reactions such as nausea, 
headache, and vertigo, were greatly reduced after the administration of Theophylline 
in pellet form as opposed to a liquid form.  The reduction of side effects in multiple 
pellet dosage forms comes from the fact that, unlike liquid, the multiple pellet dosage 
allows drugs to be absorbed gradually instead of rapidly (Shargel et al. 2004). 
Because it is difficult to compact the multiple pellets into one system, there are 
currently only a few multiple-unit tablet 
products available.  They include Beloc® 
ZOK, Antra® MUPS, and Prevacid® 
SoluTbTM.  The difficulties in compaction 
arise when trying to fuse the pellets 
together without fusing them mistakenly 
into non-disintegrating matrixes.  If the 
pellets are fused into a non-disintegrating 
matrix, they can no longer provide the 
benefits of a multiple-unit pellet system 
that disintegrates into individual pellets 
in the GI fluids leading to a more 
uniform concentration of active drug in 
the body (Abdul et al. 2010).  Scientists 
should, therefore, develop safe ways to 
compact pellets so that the maximum 
benefits of multiple-unit pellets can be 
available to the world of modified-release 
drugs.   
 
Figure 3: MUPS.  Source: Abdul et al. 2010   
Figure 4: Factors influencing design of MUPS. 
Source: Abdul et al. 2010 
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 TRANSDERMAL DRUGS   
Transdermal drug delivery systems have recently turned into a promising field 
of study for scientists involved in the production of extended-release drug products.  
The transdermal drug delivery system, generally in the form of a patch, is designed to 
deliver the active medication across the skin in a controlled rate over an extended 
period of time (Shargel et al. 2004).  Transdermal drug delivery systems obviously 
provide benefits over immediate-release oral dosages since the controlled rate of drug 
delivery eliminates frequent dosing which leads to dangerous plasma level peaks and 
valleys.  Transdermal drugs also seem to have added benefits over the oral modified-
release drugs.  One major benefit is that drugs administered transdermally avoid 
hepatic first-pass metabolism.  Such a feature can greatly benefit individuals who are 
hepato-compromised, since the drug avoids the liver altogether.  Transdermal delivery 
routes also completely avoid passage through the GI tract.  In this case, poorly 
bioavailable drugs can clearly take advantage of avoiding the GI tract through a 
transdermal route (Paudel et al. 2010).   
Although transdermal patches may vary, most designs store the active drug in a 
reservoir that is enclosed on one side with an impermeable backing and with an 
adhesive on the other side that contacts the skin (Prausnitz and Langer 2008).  There 
are generally four layers in a patch: an impermeable backing membrane, a drug 
reservoir, a semi-permeable membrane that may serve as a rate-limiting barrier, and an 
adhesive layer.  Nitroglycerin is a drug that is commonly administered transdermally 
and formulated in the described manner (with the four layers).  Nitroglycerin 
delivered transdermally may provide protection against angina (chest pains that results 
from a lack of oxygen-rich blood reaching heart muscles) for hours whereas as 
sublingual (oral) tablets only provide relief for a few minutes (Shargel et al. 2004).   
Although transdermal drugs do seem to be a fantastic way to administer drugs 
at a controlled rate while avoiding possible complications that arise along the GI tract, 
they have not yet taken over the controlled-release drug market because of several 
limitations.  One such limitation is that the skin, the most important natural barrier 
against the efficacy of transdermal drugs, only allows moderately lipophilic and low 
molecular weight drugs to cross over transdermally (Paudel et al. 2010).  The 
solubility of the drug across the skin rather than the concentration of the drug in the 
patch is the most important of the rate-controlling factors of a transdermal drug 
(Shargel et al. 2004).  Therefore, overcoming low skin permeability through different 
chemical and physical means has become an active field of research in order to allow 
many more pharmaceutical products entrance into the world of transdermal drugs 
(Paudel et al. 2010).  Other factors such as humidity and temperature can also affect 
the rate of absorption across the skin (Shargel et al. 2004).   
Interestingly enough, transdermal drug delivery has been proven to provide an 
even more stable blood level of drug than provided by oral dosages (Shargel et al. 
2004).    Thus, if the drug is found to be successful against transdermal barriers, 
scientists will probably be interested in manufacturing the drug almost exclusively as a 
patch because of the stable blood levels, avoidance of GI tract, and other benefits of 
transdermal drugs over oral modified-release dosages.  Many experiments have, 
therefore, been done to compare the effects of transdermal versus oral dosage forms.  
For example, a series of experiments were done to determine the dose-response effects 
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of oral versus transdermal selegiline on anti-depressant-like activity in rats.  Rats 
received selegiline orally by gavage (0-100 mg/kg) or via transdermal patches (0-4.8 
cm2; 0-8.7 mg/kg) daily for seven days.  Antidepressant-like activity was then 
determined in two ways.  The first was through the forced-swim test in which 
immobility and latency times during a five-minute forced swim test were measured.  
The latency time, which is the measurement of the swimming time from the beginning 
of the trial until the onset of immobility, increases under therapeutically effective anti-
depressants.  The second way through which anti-depressant activity was assessed was 
through assaying the cerebral cortices of the rats after day seven for MAO-A and 
MAO-B activities, since inhibition of MAO-A is an indication and requirement for 
clinical improvements in depressed patients.  Results demonstrated that selegiline is an 
effective anti-depressant, as represented in the forced-swim test after both oral and 
transdermal delivery, that the anti-depressant-like effect of selegiline requires greater 
than 70% inhibition of MAO-A activity, and that the transdermal delivery of slelgiline 
is 10-20 times more potent than the oral selegiline in producing both its anti-
depressant-like effects and in inhibiting cortical MAO-A (Gordon et al. 1999).  
Clearly, transdermal administration of selegiline, which bypasses first-pass 
metabolism, allows for the usage of lower doses than in oral administration.   
Scientists have also put massive focus on the development of a transdermal 
treatment for menopausal syndromes.  One particular experiment was done to 
determine the efficacy of Busipirone hydrochloride (BH) administration in animal 
models in the treatment of the main menopausal syndromes of hot flushes and anxiety 
(Shumilov and Touitou 2010).  With oral administration, BH is rapidly absorbed in 
the GI tract and undergoes extensive first-pass metabolism, so it has a very short 
elimination half-life.  Because of the short half-life elimination, efficient oral treatment 
requires frequent dosing.  Scientists hypothesized that administering this drug 
transdermally would avoid the drawbacks of oral treatment.  This study was therefore 
done to test the efficacy of the BH transdermal system using ethosomes (vesicular 
carriers that enhance permeation through the skin).  Figure 5 represents the plasma 
drug concentration profiles following transdermal administration of 15 mg/kg BH from 
a formulation containing 30 mg/g drug and a single dose of 3 mg/kg oral administration 
of aqueous drug solution.   
Clearly, when administered 
transdermally, the drug was 
present in rat plasma for a much 
longer period compared to the oral 
administration, 12 hours versus 4 
hours, respectively.  The 
continuous delivery of BH into the 
bloodstream under transdermal 
administration can offer sustained 
efficacy with reduced side effects, a 
huge benefit in the world of modified-release drugs.  Additionally, the application of 
BH ethosomal system on the skin of rats caused a decrease in the temperature at three 
hours after administration and continued for a total period of 6 hours, proving that 
transdermal BH could be effective against hot flushes. This should, therefore, be 
further researched in humans (Shumilov and Touitou 2010).   
Figure 5: Plasma drug concentration profile following 
transdermal versus oral administration of BH. 
Source: Shumilov and Touitou 2010 
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Another study was done to compare the efficacy of the Lidocaine Patch 5%, a 
transdermal, noninvasive treatment, versus Naproxen 500 mg two times daily for the 
treatment of Carpal Tunnel Syndrome.  Results of this experiment proved that 
Lidocaine Patch 5% provided a comparable level of pain relief to the oral alternative 
while avoiding risk factors associated with systemic and invasive treatments 
(Nalamachu et al. 2006).   
Transdermal delivery definitely presents an attractive alternative to the oral 
delivery of drugs.  Transdermal delivery has provides an advantage for poorly 
bioavailable drugs in that it avoids hepatic first-pass metabolism (which can 
prematurely metabolize drugs) and the GI tract (Prausnitz and Langer 2008 and 
Gordon et al. 1999).  Transdermal delivery of drugs also eliminates frequent dosing 
and allows for steady, controlled delivery which lowers plasma level peaks and valleys 
(Paudel et al. 2010).  Transdermal drugs are also non-invasive and can generally be 
self-administered—a big advantage for patients requiring long-term treatment (Paudel 
et al. 2010).  The advantages of the transdermal route over the conventional oral route 
have led to much interest in producing modified-release drugs through a transdermal 
route.  Eventually, when transdermal challenges, such as permeation of the 
hydrophobic skin barrier and possible skin irritation from patches, are eliminated, 
transdermal drugs may become a popular choice on the modified-release drug market.   
IMPLANTABLE DRUG DELIVERY SYSTEMS 
In the late 1930s, Deasby and Parkes began researching sustained release 
implantable drug delivery systems as a possible solution to the problem of high plasma 
concentrations of drugs that may lead to toxicity or low drug levels that may cause 
sub-therapeutic levels found with immediate-release products (Dash and Cudworth 
1998).  This relatively novel idea involves implanting a drug delivery system that has 
been previously modified to release the active drug in a controlled manner into the 
human body at a specific location.  Implantable systems are geared specifically to 
deliver drugs to a specific site, thereby reducing the amount of drug necessary and 
limiting its side effects, since the drug does not have to travel throughout the body 
before reaching its target.  Pharmaceutical literature has shown that when the drug 
used is selective to its site of action, fewer drugs need to be administered.  In this 
manner, drugs which were previously too unstable to administer in-vivo because of 
bodily temperature and pH conditions that may diminish the drug’s efficacy can now 
be administered directly to the site requiring treatment.  Another advantage of 
implantable drug delivery systems over conventional oral dosages is that while an oral 
dose may need to be administered one, two, or even multiple times daily, some of the 
implantable systems have been developed to last as long as five years with minimal 
monitoring as opposed to administering the oral dose one, two, or even multiple times 
daily (Dash and Cudworth 1998).  These advantages notwithstanding, since the 
system is to be implanted, care must be taken that it be biocompatible with the human 
environment.  All materials used must be chemically inert, non-carcinogenic, 
hypoallergenic, and mechanically stable so that the human body does not reject the 
implantable system.   
There are two main classes of implantable drug delivery: drug implants and 
implantable pumps containing the drug (Dash and Cudworth 1998).  The class of drug 
implants can be further divided into non-degradable and biodegradable implant 
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systems.  One common form of the non-degradable implant system is the matrix 
system. In this system, the drug is dispersed inside the matrix material, and slow 
diffusion of the drug out of the matrix provides sustained release of the drug.  
However, the kinetic release of the drug is not at a constant (zero-order) rate since it 
depends on the volume fraction of the drug ingredient in the matrix.  A non-zero order 
release rate can be hard to handle in sustained-release drugs since it is difficult to 
predict its rate of release.  A second common form is the reservoir-type system which 
contains a compact drug core within a permeable non-degradable membrane.  The 
permeability and thickness of this membrane controls the rate of diffusion of the drug 
into the body.  This type of system generally releases its drug at a constant zero-order 
kinetic release rate because the drug is released based on the properties of diffusion; as 
soon as some drug is swept away by the surrounding material in the body, more drug 
diffuses out of the reservoir, leading to the constant rate of diffusion (Dash and 
Cudworth 1998).  Levonorgesterol (LNG), a sustained-release birth control, is the 
most commonly used reservoir system.  In this system, the hormone LNG is 
encapsulated in a silicone membrane and is implanted on the underside of the upper 
arm.  This LNG system has been proven to effectively provide sustained-release of 
LNG for up to five years.   
However, there are still some problems with non-degradable implants that 
prevent such a system from being an extremely popular sustained-release route.  One 
issue is that minor surgery is required to insert and remove the implant system, 
especially with non-degradable systems because they do not disintegrate in the body.  
Additionally, there is also the fear that the membrane will rupture and lead to “drug 
dumping,” causing drug-plasma concentration to exceed maximum safety levels and 
have toxic side effects.  This fear is especially relevant with reservoir systems because 
the membrane is the only barrier blocking the drug from diffusing throughout the 
body, unlike the matrix systems in which the drug must first dissolve out of the matrix 
and then out of the membrane.  Therefore, although implantable systems do seem like 
a fantastic approach to modified-release drugs, there are clearly some factors that 
make scientists wary of its use.  Biodegradable drug implant systems improve a bit 
upon non-degradable drugs since the polymers used in biodegradable systems are 
eventually absorbed or excreted by the body.  Surgery to remove the system is 
avoided, so patients are more accepting to the idea of an implantable drug.  However, 
since the polymers in such a system are biodegradable, many added factors have to be 
considered.  For example, in order to maintain the sustained-release characteristics of 
the drug in-vivo, the degradation rate of the polymer must be maintained at a constant 
rate as well as the drug, since the release kinetics, solubility, and diffusion of the drug 
depend upon the degradation of the polymer (Dash and Cudworth 1998).  Factors 
such as pH, temperature, and increased surface area can lead to early erosion of the 
degradable system.  All of these factors, therefore, become a major challenge when 
developing a biodegradable system with extended-release goals.  The reservoir and 
matrix systems of biodegradable implants are similar to the non-degradable systems 
except for the fact that the material used in biodegradable implants is degraded in-vivo 
at a controlled rate as the drug is released.   
The second major class of implantable drug delivery systems is the implantable 
pump containing the drug.  Implantable pumps provide precise control of delivery rate 
that biodegradable and non-degradable systems cannot provide. Pump systems have 
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been made possible through advances in micro technology which developed small 
enough pumps that release drugs at a controlled rate as result of an electronically 
generated pressure difference gradient (Dash and Cudworth 1998).  Implantable drug 
delivery systems have definitely created a breakthrough in sustained-release drug 
therapy.  However, the limitations mentioned above, such as possible dose dumping 
and the need for surgery, along with the costliness of these products limits the use of 
implantable systems.  Hopefully, the future will bring possible methods to lower the 
cost of these products so that implantable drug delivery systems can be used as 
standard therapeutic practice. 
CONCLUSION 
Oral, transdermal, and implantable extended-release drug products definitely 
offer many important advantages over immediate-release dosage forms.  The most 
important advantage is that extended-release characteristics allow for a sustained 
therapeutic drug-blood level, providing a clinical response in patients that lasts much 
longer and steadier than with immediate-release products.  This sustained therapeutic 
level also reduces fluctuations between a drug-plasma minimum and maximum that 
comes from a multiple dose regimen of an immediate-release product.  In this manner, 
the side effects that come as result of the highly fluctuating drug-blood concentrations, 
such as toxicity and sub-therapeutic levels, are basically eliminated.  Another 
advantage of extended-release products is that such products generally lead to better 
patient compliance, because taking an extended-release oral dosage once a day, 
applying a patch once a week, or inserting a pump that lasts five years, is much more 
convenient than having to remember to take the dosage multiple times a day to 
maintain a therapeutic level.  Clearly, drugs with a short half-life, which under 
immediate-release characteristics would need to be given frequently, will greatly 
benefit from an extended-release formulation that can lower dosage frequency and 
maintain efficacy over a longer duration of time.   
One major concern that came with the introduction of extended-release drugs 
was that although extended-release products would lower fluctuations, they would not 
provide the same effective therapeutic levels as the immediate-release counterpart.  
However, all of the studies mentioned in this paper show that the extended-release 
products do provide the same effective therapeutic effects along with the benefit of 
lowering fluctuations of the blood-drug levels.   
However, some concerns have yet to be resolved. One such concern is the 
possibility of dose dumping and the difficulty of removing the spilled drug from the 
body.  Immediate-release products definitely have the benefit over extended-release 
products in this case since it is a much smaller dosage that is causing the adverse 
reaction and is, therefore, not as toxic, and it is also easier to remove.  Another concern 
is the lack of in-vivo testing conducted on human models.  In-vivo testing on human 
models is crucial since different gastro-intestinal factors and in-vivo characteristics can 
perhaps interact with the different formulations in possibly destructive ways.  Ideally, 
the study should be done on patients with the disease the drug is meant to treat in 
order to see if and how the disease affects the release rate and/or efficacy of the drug.  
Sometimes, slight differences between different individuals, such as caloric content of a 
meal, body temperature, and weight, can also affect drug release and must, therefore, 
be taken into account.  It may not either be worthwhile to formulate an oral extended-
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release drug for products that are administered at high dosages for the practical reason 
that the size of the pill will be too large to swallow. Therefore, all these factors must 
been studied extensively to determine the cost/benefit ratio of the extended-release 
drug.     
Clearly, there are a couple of considerations that must be acknowledged when 
dealing with extended-release products. More research should be done in-vivo to 
determine if the disadvantages of the extended-release products can be reduced, 
thereby providing the benefits of lowering fluctuations in blood-drug plasma and 
maintaining a homeostatic profile without the added disadvantages.  For example, 
further research should determine whether products demonstrate sustained-release 
characteristics without dose dumping and if products are consistent with minimum 
patient-patient variations.  Further research should also definitely be done on 
transdermal and implantable drugs since they have the benefit of completely avoiding 
the intricacies of the gastro-intestinal tract.  Perhaps the transdermal and implantable 
methods can be applied to many more drug products, thereby benefitting patients in 
the long run.  
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